Physician profile
John Chang
NPI 1780692517
$3,384.83
in general payments reported to CMS, 2019-2025
29 companies · $913 in 2025
The $913 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $194 · 2021: $353 · 2022: $292 · 2023: $357 · 2024: $612 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,882.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,356.31 | 2019-2025 | Rinvoq, Skyrizi, Creon |
| Janssen Biotech, INC. | $300.97 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $159.73 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $152.23 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $152.04 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $151.54 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.57 | 2019-2024 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $127.14 | 2025 | Rezdiffra |
| Romark Laboratories, Lc | $104.60 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $101.43 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $74.36 | 2019-2025 | Entyvio |
| Pfizer INC. | $71.55 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.72 | 2019 | |
| Celgene Corporation | $53.85 | 2021-2024 | Zeposia |
| Braintree Laboratories, INC. | $51.35 | 2021-2023 | Sutab |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $49.75 | 2019 | |
| Lucid Diagnostics INC. | $34.11 | 2023 | |
| Ironwood Pharmaceuticals, INC | $32.18 | 2022-2023 | Linzess |
| Ucb, INC. | $30.78 | 2019 | |
| Intra-Sana Laboratories | $23.30 | 2022 | |
| Medtronic, INC. | $23.28 | 2024 | Gi Genius |
| Lilly USA, LLC | $22.78 | 2025 | Omvoh |
| Aimmune Therapeutics, INC. | $17.63 | 2025 | Zenpep |
| Redhill Biopharma INC. | $16.97 | 2024 | Talicia, Aemcolo |
| Shield Therapeutics INC | $15.14 | 2025 | |
| Horizon Therapeutics Plc | $14.64 | 2022 | |
| Dynasplint Systems INC. | $14.00 | 2025 | Dynasplint |
| Vivus LLC | $12.89 | 2021 | |
| Allergan, INC. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.